A systematic review of radical antegrade modular pancreatosplenectomy for adenocarcinoma of the body and tail of the pancreas

Zhou, Yanming; Shi, Bin; Wu, Lupeng; Si, Xiaoying

doi:10.1016/j.hpb.2016.07.014

“…In the system evaluation of Zhou in 2017, 13 clinical studies including 354 patients with RAMPS were included, and the R0 resection rate reached 88%, and the 5-year survival rate reached 37%. Compared with SRPS, RAMPS is associated with less bleeding, more lymph node dissection, and a higher R0 resection rate [22].…”

Section: Discussionmentioning

confidence: 99%

“…Published reports describe an R0 resection rate of 50-74% in distal adenocarcinoma in studies with large sample sizes (n > 100 patients) [20,21]. A systematic review of radical antegrade modular pancreatosplenectomy, which identified 13 observational studies involving 354 patients undergoing RAMPS, showed that the R0 resection rate was 88% [22]. According to these studies, we used a two-sided logrank test, which requires about 23-123 patients in each group with 80% power at the 0.05 level of significance (NCSS and PASS 11 (NCSS Statistical Software, Kaysville, UT, USA)).…”

Section: Sample Size {14}mentioning

confidence: 99%

Robotic radical antegrade modular pancreatosplenectomy (RAMPS) versus standard retrograde pancreatosplenectomy (SRPS): study protocol for a randomized controlled trial

Zhang

¹

,

Kang

²

,

Zhang

³

et al. 2020

Trials

6

0

View full text Add to dashboard Cite

Background: Data from meta-analysis suggest that robotic radical antegrade modular pancreatosplenectomy (RAMPS) is a safe and effective procedure for treating adenocarcinoma in the body or tail of the pancreas, and is oncologically superior to standard retrograde pancreatosplenectomy (SRPS). RAMPS is an operation that actively expands the scope of resection, and achieves a higher R0 resection rate and lymph nodes acquisition through expanded resection. However, previous studies on RAMPS were conducted under open and laparoscopic surgery. Robotic surgery, on the other hand, plays a role in ergonomics and offers several advantages, including less fatigue, tremor filtering, 7°of wrist-like motion, motion scaling, and three-dimensional vision. At present, there is still a worldwide lack of clinical studies to observe the safety and clinical efficacy of robotic RAMPS. Hence, prospective randomized controlled trials (RCTs) comparing robotic RAMPS and SRPS are required. We begin an RCT to compare short-term surgical and oncological outcomes of robotic RAMPS and SRPS in patients undergoing distal pancreatectomy. Methods: This is a randomized, single-center clinical trial. All participants are adult patients with primary pancreatic cancer, who are undergoing RAMPS or SRPS. The primary endpoints are R0 rate (resection margins are classified by a margin to tumor distance ≥ 1 mm). The secondary endpoints are the number of harvested lymph nodes, perioperative complications and perioperative indicators (duration of surgery, blood loss, blood transfusion volume, costs). Discussion: We are undertaking a prospective RCT to evaluate the surgical and oncological outcomes of robotic RAMPS. This procedure may become a standard approach to robotic pancreatosplenectomy.

show abstract

“…In the system evaluation of Zhou in 2017, 13 clinical studies including 354 patients with RAMPS were included, and the R0 resection rate reached 88%, and the 5year survival rate reached 37%. Compared with SRPS, it has less bleeding, more lymph node dissection and higher R0 resection rate [22].…”

Section: Discussionmentioning

confidence: 99%

Robotic radical antegrade modular pancreatosplenectomy(RAMPS) versus standard retrograde pancreatosplenectomy (SRPS):study protocol for a randomized controlled trial

Zhang

¹

,

Liu²,

Kang

³

et al. 2020

Preprint

0

View full text Add to dashboard Cite

Background There has been data from meta-analysis suggesting that RAMPS is a safe and effective procedure for adenocarcinoma in the body or tail of the pancreas and is oncologically superior to SRPS. However, previous studies on RAMPS were conducted under the open and laparoscopic surgery. Robotic surgery, on the other hand, plays a role in ergonomics and offers several advantages, including less fatigue, tremor filtering, 7° of wrist-like motion, motion scaling, and three-dimensional vision. At present, there is still a lack of clinical studies to observe the safety and clinical efficacy of Robotic RAMPS in the world. Hence,prospective randomized controlled trials (RCTs) comparing Robotic RAMPS and SRPS are required. We begin a RCT trial to compare short-term surgical and oncological outcomes of Robotic RAMPS and SRPS for patients with distal pancreatectomy.Methods This is a randomized, single-center clinical trial. All included adults are patients with primary carcinoma of the distal pancreatectomy. A total of 246 patients will be randomly allocated to Robotic RAMPS or SRPS. The primary endpoints are oncological outcomes(R0 rate, number of Lymph node). Secondary endpoints are the perioperative complications, Perioperative indicators(operative time,blood loss,blood transfusion volume,costs).Discussion To evaluate the surgical and oncological outcomes of Robotic RAMPS, we therefore undertake a prospective RCT. This procedure may become a standard approach to robotic pancreatosplenectomy.

show abstract

“…In the system evaluation of Zhou in 2017, 13 clinical studies including 354 patients with RAMPS were included, and the R0 resection rate reached 88%, and the 5year survival rate reached 37%. Compared with SRPS, it has less bleeding, more lymph node dissection and higher R0 resection rate [23].…”

Section: Discussionmentioning

confidence: 99%

“…Published literatures with large sample size (n > 100) of distal adenocarcinoma demonstrate R0 resection rate of 50%-74% [21,22]. A systematic review of radical antegrade modular pancreatosplenectomy which identified 13 observational studies involving 354 patients undergoing RAMPS showed that the R0 resection rate was 88% [23] . According to these studies, we used a two-sided log-rank test which requires about 23-123 patients in each group with 80% power at the 0.05 level of significance (NCSS and PASS 11…”

Section: Sample Size {14}mentioning

confidence: 99%

Robotic radical antegrade modular pancreatosplenectomy(RAMPS) versus standard retrograde pancreatosplenectomy (SRPS):study protocol for a randomized controlled trial

Zhang

¹

,

Liu²,

Kang

³

et al. 2020

Preprint

0

View full text Add to dashboard Cite

Background There has been data from meta-analysis suggesting that RAMPS is a safe and effective procedure for adenocarcinoma in the body or tail of the pancreas and is oncologically superior to SRPS. However, previous studies on RAMPS were conducted under the open and laparoscopic surgery. Robotic surgery, on the other hand, plays a role in ergonomics and offers several advantages, including less fatigue, tremor filtering, 7° of wrist-like motion, motion scaling, and three-dimensional vision. At present, there is still a lack of clinical studies to observe the safety and clinical efficacy of Robotic RAMPS in the world. Hence,prospective randomized controlled trials (RCTs) comparing Robotic RAMPS and SRPS are required. We begin a RCT trial to compare short-term surgical and oncological outcomes of Robotic RAMPS and SRPS for patients with distal pancreatectomy.Methods This is a randomized, single-center clinical trial. All included adults are patients with primary carcinoma of the distal pancreatectomy. A total of 246 patients will be randomly allocated to Robotic RAMPS or SRPS. The primary endpoints are oncological outcomes(R0 rate, number of Lymph node). Secondary endpoints are the perioperative complications, Perioperative indicators(operative time,blood loss,blood transfusion volume,costs).Discussion To evaluate the surgical and oncological outcomes of Robotic RAMPS, we therefore undertake a prospective RCT. This procedure may become a standard approach to robotic pancreatosplenectomy.

show abstract

A systematic review of radical antegrade modular pancreatosplenectomy for adenocarcinoma of the body and tail of the pancreas

Abstract: The current literature provides supportive evidence that RAMPS is a safe and effective procedure for adenocarcinoma in the body or tail of the pancreas, and is oncologically superior to SRPS.

Cited by 42 publications

References 25 publications

Robotic radical antegrade modular pancreatosplenectomy (RAMPS) versus standard retrograde pancreatosplenectomy (SRPS): study protocol for a randomized controlled trial

Robotic radical antegrade modular pancreatosplenectomy (RAMPS) versus standard retrograde pancreatosplenectomy (SRPS): study protocol for a randomized controlled trial

Robotic radical antegrade modular pancreatosplenectomy(RAMPS) versus standard retrograde pancreatosplenectomy (SRPS):study protocol for a randomized controlled trial

Robotic radical antegrade modular pancreatosplenectomy(RAMPS) versus standard retrograde pancreatosplenectomy (SRPS):study protocol for a randomized controlled trial

Contact Info

Product

Resources

About